Home › Calculator › SRNE Dividend Calculator 2026
SRNE Dividend DRIP Calculator 2026
285714.29% YieldHealthcareSorrento Therapeutics, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When SRNE pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your SRNE snowball 📈
$10,000 in SRNE → $1.275913425261979e+46M in 10 years · $1,063,260,824,299,088,700,000,000,000,000,000,000,000,000,000,000,000.00/month
About Sorrento Therapeutics, Inc. (SRNE) — Dividend Analysis 2026
Sorrento Therapeutics, Inc. is a biopharmaceutical company, active in both clinical development and commercial operations, dedicated to creating treatments for a range of serious conditions including cancer, autoimmune disorders, inflammatory diseases, viral infections, and neurodegenerative ailments. The company's operations are divided into two distinct segments: Sorrento Therapeutics and Scilex. A core focus lies in cancer therapeutics, where Sorrento harnesses its proprietary G-MAB antibody library. This is complemented by advanced, targeted delivery systems such as chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, antibody-drug conjugates, and innovative bispecific antibody approaches. Additionally, their Sofusa drug delivery technology offers a unique method for introducing biologics directly into the lymphatic system. Sorrento's clinical pipeline features several promising candidates. These include an anti-CD38 CAR-T therapy currently being developed for multiple myeloma, amyloidosis, and graft-versus-host disease. They are also advancing resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin, for managing late-stage cancer pain and osteoarthritis knee pain. Furthermore, ZTlido, a lidocaine delivery system, addresses postherpetic neuralgia. Other significant developments comprise SEMDEXA, an injectable viscous gel in Phase III trials for sciatica, a specific form of low back pain; SP-103, an investigational non-aqueous lidocaine topical system targeting chronic low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for fibromyalgia treatment. The company actively engages in strategic collaborations, including partnerships with SmartPharm Therapeutics Inc. to develop a gene-encoded antibody vaccine against COVID-19, and with Celularity, Inc. for a Phase I/II clinical study involving up to 94 COVID-19 patients. Sorrento also works with the Mount Sinai Health System on COVI-SHIELD, an antibody therapy designed to combat SARS-CoV-2 infection, and with the Mayo Clinic on a Phase Ib pilot study utilizing the Sofusa lymphatic drug delivery technology for Ipilimumab in melanoma patients. Established in 2006, Sorrento Therapeutics, Inc. is headquartered in San Diego, California.
Compare SRNE with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full SRNE DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SRNE position with:
🌍 SRNE Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold SRNE.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 285714.29% | 285711.49% | $28,571,429 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 242857.15% | 242854.35% | $24,285,715 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 228571.43% | 228568.63% | $22,857,143 / yr |
| 🇬🇧 UK ISA | 0% | 285714.29% | 285711.49% | $28,571,429 / yr |
| 🇬🇧 UK Taxable | 8.75% | 260714.29% | 260711.49% | $26,071,429 / yr |
| 🇨🇦 TFSA | 0% | 285714.29% | 285711.49% | $28,571,429 / yr |
| 🇨🇦 CA Taxable | 25% | 214285.72% | 214282.92% | $21,428,572 / yr |
| 🇦🇺 Super (pension) | 15% | 242857.15% | 242854.35% | $24,285,715 / yr |
| 🇦🇺 AU Taxable | 30% | 200000.00% | 199997.20% | $20,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 210357.15% | 210354.35% | $21,035,715 / yr |
| 🇫🇷 FR Taxable | 30% | 200000.00% | 199997.20% | $20,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 SRNE Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 SRNE Dividend Payment Schedule
SRNE pays quarterly — 4 times per year. Next ex-div: TBD.
📊 SRNE vs Healthcare Benchmarks
How SRNE compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SRNE sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ SRNE Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| X-InTheMoney | 2023-03-17 | 19,500 | $0.80 | $15.7K | ||
| D-Return | 2023-03-17 | 195 | $0.80 | $157.00 | ||
| X-InTheMoney | 2022-12-21 | 300 | $5.50 | $1.6K | ||
| X-InTheMoney | 2022-12-02 | 200 | $5.50 | $1.1K | ||
| X-InTheMoney | 2022-12-02 | 2 | — | — | ||
| X-InTheMoney | 2022-12-21 | 3 | — | — | ||
| A-Award | 2022-12-15 | 1,500,000 | — | — | ||
| Buy | 2022-09-07 | 88,888 | $2.02 | $179.3K | ||
| Buy | 2022-09-07 | 759 | $12.00 | $9.1K | ||
| Buy | 2022-09-07 | 129 | $12.00 | $1.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SRNE dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Sorrento Therapeutics, Inc. (SRNE) is currently trading at $0.00, 100% below its 52-week high. The current dividend yield is 285714.29% based on an annual payout of $2.00 per share.
SRNE (Sorrento Therapeutics, Inc.) — 285714.29% Dividend Yield Analysis
Sorrento Therapeutics, Inc. (SRNE) is a healthcare stock currently trading at $0.00 with a dividend yield of 285714.29%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (285714.29%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.